AstraZeneca and Oracle team up on AI to find patients for drug trials

AstraZeneca and Oracle signed a non-binding term sheet to use AI and de-identified patient health data to speed up recruitment for clinical trials. The first programme launches in Abu Dhabi with healthcare firm M42, targeting patients with uncontrolled high blood pressure, with later projects planned in the US, Middle East and Europe. Financial terms were not disclosed.

• First programme in Abu Dhabi with M42 targets uncontrolled hypertension patients
• Patient data is de-identified; AstraZeneca will not see who patients are
• Later projects cover cancer, heart, kidney, lung, immune and rare diseases
• Deal value undisclosed; firms signed a non-binding term sheet